Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
GlaxoSmithKline PLC ADR is a drug manufacturers-general business based in the US. GlaxoSmithKline shares (GSK) are listed on the NYSE and all prices are listed in US Dollars. GlaxoSmithKline employs 90,096 staff and has a trailing 12-month revenue of around $37.2 billion.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $29.46 |
|---|---|
| 52-week range | $28.47 - $46.91 |
| 50-day moving average | $35.70 |
| 200-day moving average | $41.68 |
| Wall St. target price | $54.29 |
| PE ratio | 11.1973 |
| Dividend yield | $0.863 (8.46%) |
| Earnings per share (TTM) | $2.56 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $29.46 from 2022-09-28
| 1 week (2022-09-22) | -1.83% |
|---|---|
| 1 month (2022-08-29) | -11.02% |
| 3 months (2022-06-29) | -32.69% |
| 6 months (2022-03-29) | -31.95% |
| 1 year (2021-09-29) | -23.14% |
|---|---|
| 2 years (2020-09-29) | -21.29% |
| 3 years (2019-09-27) | 42.34 |
| 5 years (2017-09-29) | 33.0647 |
Valuing GlaxoSmithKline stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GlaxoSmithKline's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
GlaxoSmithKline's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, GlaxoSmithKline shares trade at around 11x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
GlaxoSmithKline's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3332. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GlaxoSmithKline's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
GlaxoSmithKline's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $11.1 billion.
The EBITDA is a measure of a GlaxoSmithKline's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $37.2 billion |
|---|---|
| Operating margin TTM | 23.48% |
| Gross profit TTM | $22.7 billion |
| Return on assets TTM | 6.58% |
| Return on equity TTM | 24.71% |
| Profit margin | 12.24% |
| Book value | $8.13 |
| Market capitalisation | $57.9 billion |
TTM: trailing 12 months
Dividend payout ratio: 46.04% of net profits
Recently GlaxoSmithKline has paid out, on average, around 46.04% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 8.46% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), GlaxoSmithKline shareholders could enjoy a 8.46% return on their shares, in the form of dividend payments. In GlaxoSmithKline's case, that would currently equate to about $0.863 per share.
While GlaxoSmithKline's payout ratio might seem fairly standard, it's worth remembering that GlaxoSmithKline may be investing much of the rest of its net profits in future growth.
GlaxoSmithKline's most recent dividend payout was on 5 October 2022. The latest dividend was paid out to all shareholders who bought their shares by 18 May 2022 (the "ex-dividend date").
GlaxoSmithKline's shares were split on a 1226:1000 basis on 21 July 2022. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1226 shares. This wouldn't directly have changed the overall worth of your GlaxoSmithKline shares – just the quantity. However, indirectly, the new 18.4% lower share price could have impacted the market appetite for GlaxoSmithKline shares which in turn could have impacted GlaxoSmithKline's share price.
Over the last 12 months, GlaxoSmithKline's shares have ranged in value from as little as $28.47 up to $46.913. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while GlaxoSmithKline's is 0.2588. This would suggest that GlaxoSmithKline's shares are less volatile than average (for this exchange).
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc. ; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
